| 1 |
30721106 | Detection of hemophagocytic extremely multinucleated giant plasma cells after rituximab/low-dose lenalidomide treatment in CD20+ multiple myeloma. | 2019 Sep |
1 |
| 2 |
31406628 | Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide. | 2019 |
1 |
| 3 |
27980307 | Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance. | 2016 |
1 |
| 4 |
25547653 | Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells. | 2015 |
1 |
| 5 |
25632047 | Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas. | 2015 Apr 15 |
1 |
| 6 |
26002964 | Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds. | 2015 Jul 2 |
1 |
| 7 |
25313353 | Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells. | 2014 |
1 |
| 8 |
22171982 | Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner. | 2012 Apr |
1 |
| 9 |
18628480 | lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. | 2008 Jul 15 |
1 |
| 10 |
18772452 | Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. | 2008 Dec 15 |
5 |